ArticleAnnals of hematology2026

Chronic portal hypertension following inotuzumab ozogamicin in a low-risk patient: a case of overriding baseline risk and long-term management.

Jinchun Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.